230 related articles for article (PubMed ID: 23066034)
1. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.
He J; Liu Z; Zheng Y; Qian J; Li H; Lu Y; Xu J; Hong B; Zhang M; Lin P; Cai Z; Orlowski RZ; Kwak LW; Yi Q; Yang J
Cancer Res; 2012 Dec; 72(24):6393-402. PubMed ID: 23066034
[TBL] [Abstract][Full Text] [Related]
2. Rev-erbα Negatively Regulates Osteoclast and Osteoblast Differentiation through p38 MAPK Signaling Pathway.
Kim K; Kim JH; Kim I; Seong S; Kim N
Mol Cells; 2020 Jan; 43(1):34-47. PubMed ID: 31896234
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.
Yang J; He J; Wang J; Cao Y; Ling J; Qian J; Lu Y; Li H; Zheng Y; Lan Y; Hong S; Matthews J; Starbuck MW; Navone NM; Orlowski RZ; Lin P; Kwak LW; Yi Q
Leukemia; 2012 Sep; 26(9):2114-23. PubMed ID: 22425892
[TBL] [Abstract][Full Text] [Related]
4. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
5. MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption.
He Z; He J; Liu Z; Xu J; Yi SF; Liu H; Yang J
Biochimie; 2014 Nov; 106():24-32. PubMed ID: 25066918
[TBL] [Abstract][Full Text] [Related]
6. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
Pennisi A; Li X; Ling W; Khan S; Gaddy D; Suva LJ; Barlogie B; Shaughnessy JD; Aziz N; Yaccoby S
Br J Haematol; 2009 Jun; 145(6):775-87. PubMed ID: 19388929
[TBL] [Abstract][Full Text] [Related]
8. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
10. Myeloma bone disease.
Sezer O
Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
[TBL] [Abstract][Full Text] [Related]
11. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
12. The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
Yang Y; Blair HC; Shapiro IM; Wang B
J Biol Chem; 2015 Jul; 290(27):16918-28. PubMed ID: 25979341
[TBL] [Abstract][Full Text] [Related]
13. 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1.
Lee JM; Park H; Noh AL; Kang JH; Chen L; Zheng T; Lee J; Ji SY; Jang CY; Shin CS; Ha H; Lee ZH; Park HY; Lee DS; Yim M
J Immunol; 2012 Dec; 189(11):5284-92. PubMed ID: 23109727
[TBL] [Abstract][Full Text] [Related]
14. P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption.
Tao H; Okamoto M; Nishikawa M; Yoshikawa H; Myoui A
PLoS One; 2011; 6(8):e23199. PubMed ID: 21886782
[TBL] [Abstract][Full Text] [Related]
15. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
Liu H; He J; Bagheri-Yarmand R; Li Z; Liu R; Wang Z; Bach DH; Huang YH; Lin P; Guise TA; Gagel RF; Yang J
Nat Commun; 2022 Jun; 13(1):3684. PubMed ID: 35760800
[TBL] [Abstract][Full Text] [Related]
16. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
17. Cafestol has a weaker inhibitory effect on osteoclastogenesis than kahweol and promotes osteoblast differentiation.
Fukuma Y; Sakai E; Nishishita K; Okamoto K; Tsukuba T
Biofactors; 2015; 41(4):222-31. PubMed ID: 26154488
[TBL] [Abstract][Full Text] [Related]
18. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CD26 signaling inhibits human osteoclast development.
Nishida H; Suzuki H; Madokoro H; Hayashi M; Morimoto C; Sakamoto M; Yamada T
J Bone Miner Res; 2014 Nov; 29(11):2439-55. PubMed ID: 24821427
[TBL] [Abstract][Full Text] [Related]
20. [Zoledronate regulates osteoclast differentiation and bone resorption in high glucose through p38 MAPK pathway].
Lin Y; Gu Y; Zuo G; Jia S; Liang Y; Qi M; Dong W
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1439-1447. PubMed ID: 33118518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]